61.40 +0.12 (0.20%)
After hours: 7:16PM EDT
|Bid||61.28 x 900|
|Ask||61.45 x 800|
|Day's range||60.55 - 62.74|
|52-week range||52.04 - 77.03|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||11.10|
|Earnings date||05 Aug 2020|
|Forward dividend & yield||2.00 (3.26%)|
|Ex-dividend date||22 Jul 2020|
|1y target est||78.87|
(Bloomberg) -- Walgreens Boots Alliance Inc. plans to cut about 4,000 jobs in the U.K. following a sharp drop in its business there and suspend stock buybacks, as the coronavirus pandemic jolts its business around the world.On Thursday, Deerfield, Illinois-based Walgreens said it anticipates full-year adjusted earnings between $4.65 to $4.75 a share, including $1.03 to $1.14 a share of costs related to Covid-19. Analysts surveyed by Bloomberg were expecting $5.43 a share. Walgreens had previously withdrawn its financial forecasts, citing the turmoil caused by the coronavirus.“As a company we are facing significant challenges and are moving fast to overcome,” Chief Executive Officer Stefano Pessina said on a call with analysts.Drugstores are grappling with both short-term disruptions and potential longer-term changes in consumer behavior driven by Covid-19. Before the pandemic set in, Walgreens was already facing questions about how it planned to compete with rivals focusing on health care and internet giants sizing up the pharmacy business.Now, the playing field has changed once again, as the global spread of Covid-19 continues to alter both the health care and retail industries in unpredictable ways.Shares of Walgreens, which had dropped 28% so far this year through Wednesday, declined as much as 7.5% in morning trading in New York.Foot traffic plummeted 85% in April at the company’s Boots stores in the U.K. amid strict lockdown orders, resulting in a $700 to $750 million hit to total sales that forced Walgreens to record a $2 billion impairment charge. Overall, sales in the quarter, which ended May 31, were essentially flat compared with the same quarter a year earlier, at $34.6 billion.In the U.S., people rushed to stock up on prescriptions and toilet paper in the early days of the pandemic. Comparable sales at U.S. drugstores rose 3%.Fewer people came into stores in the quarter, with traffic down around 20% in the quarter, Chief Financial Officer James Kehoe said on the call. Those who did come in bought more, and sales of vitamins, personal-care products and grocery items improved. But beauty sales slipped and photo plummeted.Urban markets fared much worse than rural areas in the quarter, with sales down 18% compared with an 8% increase, respectively. Executives said they haven’t seen big differences in areas with intensifying outbreaks.Soaring CostsWalgreens said that a broad decline in visits to doctors’ offices and hospitals weighed on prescription volumes. Prescriptions filled at its U.S. drugstores fell 1.3% compared with the year-ago quarter, though volumes have shown “steady improvement” since the end of May.Costs associated with cleaning stores and boosting employee pay sent selling, general and administrative expenses soaring to $8.3 billion in the quarter from $6.2 billion in the year-ago quarter.Walgreens Boots Alliance’s co-chief operating officers will now split their focus by region, with Alex Gourlay leading the U.S. and Ornella Barra overseeing the U.K. and other international businesses, Pessina said. Executives said Walgreens’ digital initiatives and new shopping options like buying online and picking up in the drive-through helped boost sales in the quarter.To help expand its health-care offerings, Walgreens said Wednesday it plans to open as many as 700 doctors’ offices in its drugstores over the next five years. Rival CVS Health Corp. has already made big steps in that direction by buying insurer Aetna and making over stores to focus on patient care.After a number of attempts at in-store clinics, Pessina said its partnership with VillageMD to bring primary-care doctors into Walgreens stores appears to be the model that fits best.Walgreens posted a loss of $1.71 billion, or $1.95 a share, in the fiscal third quarter. On an adjusted basis, earnings per share came to 83 cents. Analysts surveyed by Bloomberg expected adjusted earnings of $1.19 a share.(Updates with comments from executives beginning in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Despite some tailwinds from COVID-19, the drugstore chain doesn't expect earnings growth this year.
If you want to know who really controls CVS Health Corporation (NYSE:CVS), then you'll have to look at the makeup of...
Walgreens reports its Q3 FY20 financial results before the opening bell on Thursday, July 9. The question is should investors consider buying shares of the struggling pharmacy chain?
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) closed the most recent trading day at $64.97, moving +0.85% from the previous trading session.
PJ SOLOMON, a leading financial advisory firm and independently-operated affiliate of Natixis, announced that Syed A. Husain, RPh, has joined as a Managing Director. PJ SOLOMON has long been active in the pharmacy sector.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Merck, CVS Health, Morgan Stanley, Applied Materials and Enterprise Products Partners
The job market is on the mend as lockdowns are eased and businesses gradual reopen. May numbers surpass all expectations, indicating the start of an economic revival from the coronavirus crisis.
And last month, the pharmacy giant started a test program that uses flying drones to deliver medicine to customers.
Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply
The markets have rallied since March's market crash but bargain hunters can still scoop up many cheap buys. CVS Health (NYSE: CVS) is a well-known name in healthcare and it isn't going anywhere. The pharmacy retailer's playing an important role during the COVID-19 pandemic: Not only is it helping people get their prescriptions, but it's assisting in testing people who are concerned they may have contracted the coronavirus.
Here are three companies in the out-of-favor retail and financial sectors that are solid names whose stocks are trading toward the bottom of their historical valuation ranges. The Home Depot (NYSE: HD) has been one of the essential retailers that have remained open during the COVID-19 crisis. This means more interest in fixer-uppers, which is good news for Home Depot.
Panic and uncertainty caused by the coronavirus disease 2019 (COVID-19) pandemic pushed the broad-based S&P 500 into its fastest bear market in history in March and eventually sent the widely followed stock index down 34% in just 33 calendar days. Despite never knowing when stock market corrections will present themselves, how long they'll last, or how steep the drop will be, every correction (and bear market) in history has proven to be an excellent buying opportunity for investors with a long-term mindset. What's more, you don't have to be rolling in dough to put your money to work in the stock market.
Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. Last month, the startup dipped its autonomous toe in the healthcare field through a program to deliver food and medical supplies at temporary field hospitals in California set up in response to the COVID-19 pandemic. The pilot program centers on one CVS Pharmacy in Bellaire, Texas and will serve customers across three ZIP codes.